Sort   by:  
 Page size 
UnknownWhole genome methylation combined with RNA-seq reveals the protective effects of Gualou-Xiebai herb pair in foam cells through DNA methylation mediated PI3K-AKT signaling pathway.
Not available
S-EPMC9992180 | biostudies-literature
UnknownEffects and mechanisms of Zhizi Chuanxiong herb pair against atherosclerosis: an integration of network pharmacology, molecular docking, and experimental validation.
Not available
S-EPMC10782628 | biostudies-literature
UnknownEfficacy and safety of Jianpi Qinghua granules for non-erosive reflux disease with spleen deficiency and damp-heat syndrome: a multicenter, randomized, double-blind, placebo-controlled clinical trial.
Not available
S-EPMC11747786 | biostudies-literature
UnknownEfficacy and safety of oral Chinese patent medicines in the treatment of coronary heart disease combined with hyperlipidemia: a systematic review and network meta-analysis of 78 trials.
Not available
S-EPMC10717272 | biostudies-literature
UnknownThe causal relationship between sarcopenic obesity factors and benign prostate hyperplasia.
Not available
S-EPMC10663947 | biostudies-literature
UnknownAmelioration of AOM/DSS-Induced Murine Colitis-Associated Cancer by Evodiamine Intervention is Primarily Associated with Gut Microbiota-Metabolism-Inflammatory Signaling Axis.
Not available
S-EPMC8740177 | biostudies-literature
UnknownPharmacological Mechanisms Underlying the Anti-asthmatic Effects of Modified Guomin Decoction Determined by Network Pharmacology and Molecular Docking.
Not available
S-EPMC8100455 | biostudies-literature
UnknownPrediction of the Network Pharmacology-Based Mechanism for Attenuation of Atherosclerosis in Apolipoprotein E Knockout Mice by Panax notoginseng Saponins.
Not available
S-EPMC7193284 | biostudies-literature
UnknownBiopsychosocial factors associated with symptom severity in the overlap of non-erosive reflux disease and epigastric pain syndrome: A multicenter cross-sectional study.
Not available
S-EPMC12704865 | biostudies-literature
UnknownQuanduzhong capsules for the treatment of grade 1 hypertension patients with low-to-moderate risk: A multicenter, randomized, double-blind, placebo-controlled clinical trial.
Not available
S-EPMC9871381 | biostudies-literature
Sort   by:  
 Page size